288 related articles for article (PubMed ID: 20875858)
1. A knock-in reporter mouse model for Batten disease reveals predominant expression of Cln3 in visual, limbic and subcortical motor structures.
Ding SL; Tecedor L; Stein CS; Davidson BL
Neurobiol Dis; 2011 Feb; 41(2):237-48. PubMed ID: 20875858
[TBL] [Abstract][Full Text] [Related]
2. Developmental impairments of select neurotransmitter systems in brains of Cln3(Deltaex7/8) knock-in mice, an animal model of juvenile neuronal ceroid lipofuscinosis.
Herrmann P; Druckrey-Fiskaaen C; Kouznetsova E; Heinitz K; Bigl M; Cotman SL; Schliebs R
J Neurosci Res; 2008 Jun; 86(8):1857-70. PubMed ID: 18265413
[TBL] [Abstract][Full Text] [Related]
3. Altered gene expression in the eye of a mouse model for batten disease.
Chattopadhyay S; Kingsley E; Serour A; Curran TM; Brooks AI; Pearce DA
Invest Ophthalmol Vis Sci; 2004 Sep; 45(9):2893-905. PubMed ID: 15326100
[TBL] [Abstract][Full Text] [Related]
4. A knock-in reporter model of Batten disease.
Eliason SL; Stein CS; Mao Q; Tecedor L; Ding SL; Gaines DM; Davidson BL
J Neurosci; 2007 Sep; 27(37):9826-34. PubMed ID: 17855597
[TBL] [Abstract][Full Text] [Related]
5. Altered arginine metabolism in the central nervous system (CNS) of the Cln3-/- mouse model of juvenile Batten disease.
Chan CH; Ramirez-Montealegre D; Pearce DA
Neuropathol Appl Neurobiol; 2009 Apr; 35(2):189-207. PubMed ID: 19284480
[TBL] [Abstract][Full Text] [Related]
6. Retinal pathology and function in a Cln3 knockout mouse model of juvenile Neuronal Ceroid Lipofuscinosis (batten disease).
Seigel GM; Lotery A; Kummer A; Bernard DJ; Greene ND; Turmaine M; Derksen T; Nussbaum RL; Davidson B; Wagner J; Mitchison HM
Mol Cell Neurosci; 2002 Apr; 19(4):515-27. PubMed ID: 11988019
[TBL] [Abstract][Full Text] [Related]
7. Novel CLN3 mutation predicted to cause complete loss of protein function does not modify the classical JNCL phenotype.
Kwon JM; Rothberg PG; Leman AR; Weimer JM; Mink JW; Pearce DA
Neurosci Lett; 2005 Oct; 387(2):111-4. PubMed ID: 16087292
[TBL] [Abstract][Full Text] [Related]
8. Novel interactions of CLN3 protein link Batten disease to dysregulation of fodrin-Na+, K+ ATPase complex.
Uusi-Rauva K; Luiro K; Tanhuanpää K; Kopra O; Martín-Vasallo P; Kyttälä A; Jalanko A
Exp Cell Res; 2008 Sep; 314(15):2895-905. PubMed ID: 18621045
[TBL] [Abstract][Full Text] [Related]
9. Self-Complementary AAV9 Gene Delivery Partially Corrects Pathology Associated with Juvenile Neuronal Ceroid Lipofuscinosis (CLN3).
Bosch ME; Aldrich A; Fallet R; Odvody J; Burkovetskaya M; Schuberth K; Fitzgerald JA; Foust KD; Kielian T
J Neurosci; 2016 Sep; 36(37):9669-82. PubMed ID: 27629717
[TBL] [Abstract][Full Text] [Related]
10. Altered sensitivity of cerebellar granule cells to glutamate receptor overactivation in the Cln3(Δex7/8)-knock-in mouse model of juvenile neuronal ceroid lipofuscinosis.
Finn R; Kovács AD; Pearce DA
Neurochem Int; 2011 May; 58(6):648-55. PubMed ID: 21315126
[TBL] [Abstract][Full Text] [Related]
11. Increased expression of lysosomal acid phosphatase in CLN3-defective cells and mouse brain tissue.
Pohl S; Mitchison HM; Kohlschütter A; van Diggelen O; Braulke T; Storch S
J Neurochem; 2007 Dec; 103(6):2177-88. PubMed ID: 17868323
[TBL] [Abstract][Full Text] [Related]
12. Transcript and in silico analysis of CLN3 in juvenile neuronal ceroid lipofuscinosis and associated mouse models.
Chan CH; Mitchison HM; Pearce DA
Hum Mol Genet; 2008 Nov; 17(21):3332-9. PubMed ID: 18678598
[TBL] [Abstract][Full Text] [Related]
13. A novel c.1135_1138delCTGT mutation in CLN3 leads to juvenile neuronal ceroid lipofuscinosis.
Drack AV; Miller JN; Pearce DA
J Child Neurol; 2013 Sep; 28(9):1112-6. PubMed ID: 23877479
[TBL] [Abstract][Full Text] [Related]
14. Loss of CLN3, the gene mutated in juvenile neuronal ceroid lipofuscinosis, leads to metabolic impairment and autophagy induction in retinal pigment epithelium.
Zhong Y; Mohan K; Liu J; Al-Attar A; Lin P; Flight RM; Sun Q; Warmoes MO; Deshpande RR; Liu H; Jung KS; Mitov MI; Lin N; Butterfield DA; Lu S; Liu J; Moseley HNB; Fan TWM; Kleinman ME; Wang QJ
Biochim Biophys Acta Mol Basis Dis; 2020 Oct; 1866(10):165883. PubMed ID: 32592935
[TBL] [Abstract][Full Text] [Related]
15. Moving towards therapies for juvenile Batten disease?
Cooper JD
Exp Neurol; 2008 Jun; 211(2):329-31. PubMed ID: 18400221
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of phosphodiesterase-4 inhibitors in juvenile Batten disease (CLN3).
Aldrich A; Bosch ME; Fallet R; Odvody J; Burkovetskaya M; Rama Rao KV; Cooper JD; Drack AV; Kielian T
Ann Neurol; 2016 Dec; 80(6):909-923. PubMed ID: 27804148
[TBL] [Abstract][Full Text] [Related]
17. Defective lysosomal arginine transport in juvenile Batten disease.
Ramirez-Montealegre D; Pearce DA
Hum Mol Genet; 2005 Dec; 14(23):3759-73. PubMed ID: 16251196
[TBL] [Abstract][Full Text] [Related]
18. Retinal function in aging homozygous Cln3 (Δex7/8) knock-in mice.
Volz C; Mirza M; Langmann T; Jägle H
Adv Exp Med Biol; 2014; 801():495-501. PubMed ID: 24664736
[TBL] [Abstract][Full Text] [Related]
19. Revisiting the neuronal localization and trafficking of CLN3 in juvenile neuronal ceroid lipofuscinosis.
Oetjen S; Kuhl D; Hermey G
J Neurochem; 2016 Nov; 139(3):456-470. PubMed ID: 27453211
[TBL] [Abstract][Full Text] [Related]
20. Age-dependent alterations in neuronal activity in the hippocampus and visual cortex in a mouse model of Juvenile Neuronal Ceroid Lipofuscinosis (CLN3).
Burkovetskaya M; Karpuk N; Kielian T
Neurobiol Dis; 2017 Apr; 100():19-29. PubMed ID: 28042098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
